N

Nkarta
D

NKTX

1.76500
USD
-0.05
(-2.75%)
مغلق
حجم التداول
6,613
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
125,240,083
أصول ذات صلة
A
ALLO
-0.06500
(-5.04%)
1.22500 USD
B
BEAM
-0.230
(-1.35%)
16.750 USD
C
CRSP
-0.190
(-0.43%)
44.240 USD
E
EDIT
-0.11500
(-4.90%)
2.23000 USD
M
MGTX
-0.17600
(-2.71%)
6.32000 USD
R
RCKT
-0.13000
(-4.61%)
2.69000 USD
S
SGMO
-0.01960
(-4.05%)
0.46440 USD
VRTX
VRTX
-7.64
(-1.70%)
440.97 USD
المزيد
الأخبار المقالات

العنوان: Nkarta

القطاع: Healthcare
الصناعة: Biotechnology
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.